Is GLSI or GMAB more undervalued in 2026?

CirclFi compares Greenwich LifeSciences, Inc. (GLSI) and Genmab A/S (GMAB) using 13 institutional-grade valuation models. GLSI has a Quality of Company score of 4.0/10 while GMAB scores 6.7/10.

Which is a better buy — GLSI or GMAB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GLSI and GMAB valuations compare?

GLSI at $28.99 and GMAB at $27.04 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GLSI vs GMAB Valuation Comparison 2026 — Intrinsic Value Analysis

GLSI

Biotechnology

Greenwich LifeSciences, Inc.

Quality

4.0

out of 10

Value Trap

—

Price

$28.99

Last close

Models

6/13

Active

GMAB

Biotechnology

Genmab A/S

Quality

6.7

out of 10

Value Trap

—

Price

$27.04

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	GLSI Fair Value	GLSI Upside	GMAB Fair Value	GMAB Upside
Bayesian DCF	Intrinsic	$7.90	-72.7%	$29.51	+9.1%
Earnings Power Value	Intrinsic	—	—	$22.31	-17.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$27.15	-6.3%	$27.64	+2.2%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GLSI vs GMAB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GLSI vs GMAB — Which Stock Is More Undervalued?

GMAB scores higher with a 6.7/10 quality rating vs GLSI's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Greenwich LifeSciences, Inc. (GLSI) and Genmab A/S (GMAB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GLSI currently trades at $28.99 with a QOC of 4.0/10, while GMAB trades at $27.04 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).